PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
5.62%
Some net income increase while AVXL is negative at -3.82%. John Neff would see a short-term edge over the struggling competitor.
3.20%
D&A growth of 3.20% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
22.07%
Less SBC growth vs. AVXL's 96.54%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
81.65%
Slight usage while AVXL is negative at -5.46%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
50.82%
A yoy AP increase while AVXL is negative at -345.24%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
28.44%
Lower 'other working capital' growth vs. AVXL's 62.07%. David Dodd would see fewer unexpected short-term demands on cash.
-17.77%
Negative yoy while AVXL is 710.09%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
18.75%
Operating cash flow growth above 1.5x AVXL's 7.04%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-1425.00%
Negative yoy CapEx while AVXL is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1425.00%
We reduce yoy invests while AVXL stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-0.29%
Negative yoy issuance while AVXL is 36.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.